Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 77

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in July 2017. The industry reported 314 deals worth USD29.5 billion in July 2017, compared to 392 deals worth USD31.5 billion in June 2017. The oncology therapeutics market remained at the top in deal activity in July 2017 with 104 deals. In second place, infectious disease therapeutics market reported 60 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD203.7m as upfront payments in July 2017, compared to USD130m in June 2017. The number of deals in North America decreased to 203 in July 2017 from 254 in June 2017.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the six months.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......
$695

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......
$10995

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......
$3995

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......
$4950

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......
$995

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
$595

Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) – Global Forecast to 2025

“The animal parasiticides market is projected to grow at a CAGR of 7.2% between 2020 and 2025.” The animal parasiticides market is expected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% from 2020 to 2025. Increasing pet expenditure and the growing incidences of parasitic infections are some major factors driving the market. However, accounting for the diversity of parasitic species while developing effective medications and parasiticides is one of the major challenges for players operating in this market. “Ecto parasiticides segment to witness the highest growth rate during the forecast period.” In the market, by type, ecto parasiticides are expected to register the highest CAGR during the forecast period. The high growth of this segment......
$4950

Health Insurance Implications – Coronavirus Disease (COVID-19) Sector Impact – June 2020

Health Insurance Implications - Coronavirus Disease (COVID-19) Sector Impact - June 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Key Highlights - A number of reports estimated the impact of COVID-19 on unemployment rates and loss of E......
$495

Laboratory Information Management System (LIMS) Market by Type (Broad, Industry-specific), Component (Software, Services), Delivery (On premise, Remote, Cloud), End User (CRO, Pharma, Biotech, Chemical, Agriculture, FnB, Oil, Gas) – Global Forecast to 2025

“The global laboratory information management systems market is projected to grow at a CAGR of 12.1% during the forecast period (2020–2025)” The global LIMS market is estimated to reach USD 1.7 billion by 2025 from USD 1.0 billion in 2020, at a CAGR of 12.1%. The increasing adoption of LIMS to comply with stringent regulatory requirements, technological advancements in LIMS offerings, increasing R&D expenditure in pharmaceutical and biotechnology companies, and the growing adoption of cloud-based LIMS are some of the factors driving the growth of this market. However,the high maintenance and service costs and the lack of integration standards for LIMS are expected to restrain the growth of this market. “Services segment to grow at the highest CAGR during the forecast peri......
$4950

Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2029

Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029 Summary Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016). GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cas......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy